Alvotech and DKSH Extend their Collaboration to Commercialize Six Biosimilars in Asia

 Alvotech and DKSH Extend their Collaboration to Commercialize Six Biosimilars in Asia

Alvotech and DKSH Extend their Collaboration to Commercialize Six Biosimilars in Asia

Shot:  

  • The companies expand their strategic partnership to commercialize six new biosimilar product candidates for the Asian markets
  • In Mar’2020, the companies collaborated for AVT02 (biosimilar, adalimumab). The collaboration targets Taiwan, Korea, Hong Kong, Philippines, Vietnam, Thailand, Cambodia, Myanmar, Malaysia, Singapore, Indonesia, India, Bangladesh, and Pakistan
  • The expansion deepens the partnership b/w the two companies to accelerate the introduction of a high-quality biosimilar to patients in Asia

Click here ­to­ read full press release/ article | Ref: Alvotech | Image: Alvotech

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post